Navigation Links
IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
Date:2/5/2008

On February 5, 2008, the closing price of the Company's common stock was

$3.81 per share

IRVINE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it received a letter, dated February 4, 2008, from The NASDAQ Stock Market, notifying IDM Pharma that during the preceding 30 consecutive business days, the closing bid price of the Company's common stock had been below the $1.00 minimum bid per share required for continued listing on the NASDAQ Global Market under NASDAQ Marketplace Rule 4450(a)(5).

The NASDAQ letter dated February 4, 2008 has no immediate effect on the listing of the Company's common stock. On February 5, 2008, the closing price of the Company's common stock was $3.81 per share.

In accordance with NASDAQ Marketplace Rule 4450(e)(2), the Company will be granted 180 calendar days, or until August 4, 2008, to regain compliance with the minimum bid price requirement in accordance with NASDAQ Marketplace Rule 4450(a)(5) by maintaining a closing bid price of $1.00 per share or higher for a minimum of 10 consecutive trading days. If the Company is successful in meeting this requirement, NASDAQ will provide written notification that is has achieved compliance with the Rule. If the Company is unsuccessful in meeting the minimum bid requirement during this initial 180-day period, NASDAQ will provide notice to IDM Pharma that the Company's common stock will be delisted from the NASDAQ Global Market. If the Company receives a delisting notification, the Company may appeal to the Listing Qualifications Panel or apply to transfer its common stock to the NASDAQ Capital Market if IDM Pharma satisfies all criteria for initial listing on the NASDAQ Capital Market in accordance with Marketplace Rule 4310(c), other than compliance with the minimum bid price requirement. If the application to the NASDAQ Capital Market is approved, then the Company will have an additional 180-day compliance period in order to regain compliance with the minimum bid price requirement while listed on the NASDAQ Capital Market.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the NASDAQ Marketplace Rules. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to maintain a closing bid price of $1.00 per share or higher for a minimum of 10 consecutive trading days and risks relating to the Company's ability to comply with other NASDAQ requirements. Other risks affecting the Company and its drug development programs are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference
2. MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
3. ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
4. ARMSRx Tackles the New Rx Addiction -- Pharmacy Benefit Audits
5. NPS Pharmaceuticals to Present at BIO CEO & Investor Conference
6. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
10. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
11. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: